Table 1 Open in new tab Summary of...

Article¹	RCT² 1. Parallel 2. Cross-over	Age³; n (men/women)⁴; BMI⁵ (atorvastatin and placeboor total population)	Use of antihypertensive	Dose/weeks⁶	Group 1. Basal 2. Placebo	Jadad Scale
NORMOTENSIVE AND NORMOLIPIDAEMIC
BLESKE 2006⁵⁵	2	56.00 ± 11.00; 9/6; 29.39 ± 4.53^b	Yes	80/12	1; 2	5
JOYEUX-FAURE 2014⁵⁶	1	51.00 ± 12.00; 21/4; 28.58 ± 5.12^b;56.00 ± 9.00; 18/8; 28.70 ± 3.94^b	No	40/12	1; 2	5
MUKHERJEE 2008⁵⁷	1	47.92 ± 11.42; 40/31; 22.46 ± 3.76^b	No	10/24	2	3
ORR 2009⁵⁸	1	53.00 ± 2.00; 6/10; 31.90 ± 0.90^a;55.00 ± 3.00; 5/5; 31.10 ± 0.90^a	No	80/12	1; 2	3
PAULSEN 2008³⁵	2	33.66 ± 13.56; 13/7; 25.50 ± 3.19^b	No	80/4	2	4
PAULSEN 2010³⁶	2	51.00 ± 5.56; 15/6; 28.66 ± 4.77^b	No	80/2 days	2	4
RAJA-KHAN 2011⁵⁹	1	38.80 ± 4.30; 0/20; 40.10 ± 11.80^b;29.40 ± 5.80; 0/11; 36.00 ± 10.40^b	No	40/6	1; 2	3
RIAHI 2006⁶⁰	2	64.30 ± 8.90; 71/18; 28.40 ± 4.40^b	Yes	80/6	2	5
SZRAMKA 2007²¹	2	63.40 ± 7.17; 8/2; 29.39 ± 4.53^b	No	80/4	2	5
TERAMOTO 2014⁶¹	1	49.00 ± 8.80; 8/19; 24.00 ± 3.30^b;50.00 ± 9.60; 18/10; 25.00 ± 3.70^b	No	10/12	1; 2	5
ZALESKI 2014⁶²	1	44.10 ± 0.80; 203/216; 26.40 ± 0.20^a;44.60 ± 1.50; 104/113; 26.50 ± 0.45^a	No (n:400);Yes (n:19)	80/24	1; 2	5
ZOU 2018⁶³	1	59.30 ± 7.28; 45/30; 23.80 ± 3.15^b;61.21 ± 7.59; 37/38; 25.21 ± 4.72^b	Yes	20/48	1; 2	5
NORMOTENSIVE
RENKE 2010⁶⁴	2	34.20 ± 6.94; 7/7; ND	Yes	40/12	2	3
VRTOVEC 2005¹⁵	1	67.00 ± 13.00; 41/35; ND67.00 ± 13.00; 41/35, ND	Yes	10/12	1; 2	2
NORMOTENSIVE AND HYPERLIPIDAEMIC
HAMAAD 2005¹⁴	1	67.00 ± 10.00; 19/3; ND^b;66.00 ± 10.00; 7/2; ND^b	Yes	40/12	1; 2	3
HORWICH 2011⁵	1	47.00 ± 14.00; 5/9; 31.00 ± 7.00^a;49.00 ± 17.00; 10/2; 31.00 ± 6.00^a	Yes	3/12	1; 2	5
KADOGLOU1 2010⁶⁵	1	64.76 ± 7.31; 30/35; ND^b	Yes	10 or 20/48	1	3
KADOGLOU2 2010⁶⁵	1	63.24 ± 6.76; 30/36; ND^b	Yes	80/48	1	3
MELENOVSK 2003²⁷	2	47.00 ± 8.00; 29/0; 27.80 ± 2.00^b	No	10/10	1	3
TOKUHISA 2018⁶⁶	2	64.10 ± 11.60; 8/2; 23.00 ± 4.10^b	Yes	10/8	1	4
HYPERTENSIVE AND NORMOLIPIDAEMIC
MANISTY 2009⁶⁷	1	79.00; 127/15; 28.50 ± 4.00^b	Yes	10/72	2	3
MARTIN-VENTURA 2008⁶⁸	1	70.00 ± 7.00; 21/5; ND^a	No	20/4	1	3
HYPERTENSIVE AND HYPERLIPIDAEMIC
FASSET 2010⁶⁹	1	60.20 ± 15.10; 80/43; 28.50 ± 6.00^b;60.30 ± 15.20; 44/21; 28.60 ± 6.10^b	Yes	10/144	1; 2	5
FASSET 2010⁷⁰	1	63.55 ± 15.60; 16/16; 28.50 ± 5.55^b	Yes	10/90	1; 2	5
FOGARI 2004⁷¹	2	56.30 ± 5.10; 22/23; ND^b	Yes	20/12	1	3
KANAKI 2013⁷²	1	59.70 ± 8.80; 12/13; 29.40 ± 4.30^b;58.80 ± 10.80; 12/13; 29.60 ± 3.80^b	Yes	10/26	1; 2	3
KANAKI 2012⁷³	1	59.70 ± 8.90; 12/13; 29.40 ± 4.30^b;58.80 ± 10.80; 12/13; 29.60 ± 3.80^b	Yes	10/26	1; 2	3
KOH 2011¹¹	2	-	No	20/8	1	3
MAGEN 2004⁷⁴	1	54.10 ± 13.50; 8/7; 27.90 ± 1.80^b;51.40 ± 12.80; 7/9; 27.70 ± 2.10^b	Yes	20/8	1; 2	3
RAISON 2002⁷⁵	1	56.10 ± 9.50; 7/4; 29.30 ± 3.50^b	Yes	10/12	1	5
HYPERTENSIVE
FERRIER 2002⁷⁶	2	60.00 ± 14.00; 18/4: ND^b	No	80/12	2	5
GOMES 2010¹⁶	2	54.00 ± 16.00; 9/4; 26.70 ± 1.00^b	Yes	20/3	2	5

Article¹

RCT² 1. Parallel 2. Cross-over

Age³; n (men/women)⁴; BMI⁵ (atorvastatin and placeboor total population)

Use of antihypertensive

Dose/weeks⁶

Group 1. Basal 2. Placebo

Jadad Scale

NORMOTENSIVE AND NORMOLIPIDAEMIC

BLESKE 2006⁵⁵

56.00 ± 11.00; 9/6; 29.39 ± 4.53^b

Yes

80/12

1; 2

JOYEUX-FAURE 2014⁵⁶

51.00 ± 12.00; 21/4; 28.58 ± 5.12^b;56.00 ± 9.00; 18/8; 28.70 ± 3.94^b

40/12

1; 2

MUKHERJEE 2008⁵⁷

47.92 ± 11.42; 40/31; 22.46 ± 3.76^b

10/24

ORR 2009⁵⁸

53.00 ± 2.00; 6/10; 31.90 ± 0.90^a;55.00 ± 3.00; 5/5; 31.10 ± 0.90^a

80/12

1; 2

PAULSEN 2008³⁵

33.66 ± 13.56; 13/7; 25.50 ± 3.19^b

80/4

PAULSEN 2010³⁶

51.00 ± 5.56; 15/6; 28.66 ± 4.77^b

80/2 days

RAJA-KHAN 2011⁵⁹

38.80 ± 4.30; 0/20; 40.10 ± 11.80^b;29.40 ± 5.80; 0/11; 36.00 ± 10.40^b

40/6

1; 2

RIAHI 2006⁶⁰

64.30 ± 8.90; 71/18; 28.40 ± 4.40^b

Yes

80/6

SZRAMKA 2007²¹

63.40 ± 7.17; 8/2; 29.39 ± 4.53^b

80/4

TERAMOTO 2014⁶¹

49.00 ± 8.80; 8/19; 24.00 ± 3.30^b;50.00 ± 9.60; 18/10; 25.00 ± 3.70^b

10/12

1; 2

ZALESKI 2014⁶²

44.10 ± 0.80; 203/216; 26.40 ± 0.20^a;44.60 ± 1.50; 104/113; 26.50 ± 0.45^a

No (n:400);Yes (n:19)

80/24

1; 2

ZOU 2018⁶³

59.30 ± 7.28; 45/30; 23.80 ± 3.15^b;61.21 ± 7.59; 37/38; 25.21 ± 4.72^b

Yes

20/48

1; 2

NORMOTENSIVE

RENKE 2010⁶⁴

34.20 ± 6.94; 7/7; ND

Yes

40/12

VRTOVEC 2005¹⁵

67.00 ± 13.00; 41/35; ND67.00 ± 13.00; 41/35, ND

Yes

10/12

1; 2

NORMOTENSIVE AND HYPERLIPIDAEMIC

HAMAAD 2005¹⁴

67.00 ± 10.00; 19/3; ND^b;66.00 ± 10.00; 7/2; ND^b

Yes

40/12

1; 2

HORWICH 2011⁵

47.00 ± 14.00; 5/9; 31.00 ± 7.00^a;49.00 ± 17.00; 10/2; 31.00 ± 6.00^a

Yes

3/12

1; 2

KADOGLOU1 2010⁶⁵

64.76 ± 7.31; 30/35; ND^b

Yes

10 or 20/48

KADOGLOU2 2010⁶⁵

63.24 ± 6.76; 30/36; ND^b

Yes

80/48

MELENOVSK 2003²⁷

47.00 ± 8.00; 29/0; 27.80 ± 2.00^b

10/10

TOKUHISA 2018⁶⁶

64.10 ± 11.60; 8/2; 23.00 ± 4.10^b

Yes

10/8

HYPERTENSIVE AND NORMOLIPIDAEMIC

MANISTY 2009⁶⁷

79.00; 127/15; 28.50 ± 4.00^b

Yes

10/72

MARTIN-VENTURA 2008⁶⁸

70.00 ± 7.00; 21/5; ND^a

20/4

HYPERTENSIVE AND HYPERLIPIDAEMIC

FASSET 2010⁶⁹

60.20 ± 15.10; 80/43; 28.50 ± 6.00^b;60.30 ± 15.20; 44/21; 28.60 ± 6.10^b

Yes

10/144

1; 2

FASSET 2010⁷⁰

63.55 ± 15.60; 16/16; 28.50 ± 5.55^b

Yes

10/90

1; 2

FOGARI 2004⁷¹

56.30 ± 5.10; 22/23; ND^b

Yes

20/12

KANAKI 2013⁷²

59.70 ± 8.80; 12/13; 29.40 ± 4.30^b;58.80 ± 10.80; 12/13; 29.60 ± 3.80^b

Yes

10/26

1; 2

KANAKI 2012⁷³

59.70 ± 8.90; 12/13; 29.40 ± 4.30^b;58.80 ± 10.80; 12/13; 29.60 ± 3.80^b

Yes

10/26

1; 2

KOH 2011¹¹

20/8

MAGEN 2004⁷⁴

54.10 ± 13.50; 8/7; 27.90 ± 1.80^b;51.40 ± 12.80; 7/9; 27.70 ± 2.10^b

Yes

20/8

1; 2

RAISON 2002⁷⁵

56.10 ± 9.50; 7/4; 29.30 ± 3.50^b

Yes

10/12

HYPERTENSIVE

FERRIER 2002⁷⁶

60.00 ± 14.00; 18/4: ND^b

80/12

GOMES 2010¹⁶

54.00 ± 16.00; 9/4; 26.70 ± 1.00^b

Yes

20/3

Article¹	RCT² 1. Parallel 2. Cross-over	Age³; n (men/women)⁴; BMI⁵ (atorvastatin and placeboor total population)	Use of antihypertensive	Dose/weeks⁶	Group 1. Basal 2. Placebo	Jadad Scale
NORMOTENSIVE AND NORMOLIPIDAEMIC
BLESKE 2006⁵⁵	2	56.00 ± 11.00; 9/6; 29.39 ± 4.53^b	Yes	80/12	1; 2	5
JOYEUX-FAURE 2014⁵⁶	1	51.00 ± 12.00; 21/4; 28.58 ± 5.12^b;56.00 ± 9.00; 18/8; 28.70 ± 3.94^b	No	40/12	1; 2	5
MUKHERJEE 2008⁵⁷	1	47.92 ± 11.42; 40/31; 22.46 ± 3.76^b	No	10/24	2	3
ORR 2009⁵⁸	1	53.00 ± 2.00; 6/10; 31.90 ± 0.90^a;55.00 ± 3.00; 5/5; 31.10 ± 0.90^a	No	80/12	1; 2	3
PAULSEN 2008³⁵	2	33.66 ± 13.56; 13/7; 25.50 ± 3.19^b	No	80/4	2	4
PAULSEN 2010³⁶	2	51.00 ± 5.56; 15/6; 28.66 ± 4.77^b	No	80/2 days	2	4
RAJA-KHAN 2011⁵⁹	1	38.80 ± 4.30; 0/20; 40.10 ± 11.80^b;29.40 ± 5.80; 0/11; 36.00 ± 10.40^b	No	40/6	1; 2	3
RIAHI 2006⁶⁰	2	64.30 ± 8.90; 71/18; 28.40 ± 4.40^b	Yes	80/6	2	5
SZRAMKA 2007²¹	2	63.40 ± 7.17; 8/2; 29.39 ± 4.53^b	No	80/4	2	5
TERAMOTO 2014⁶¹	1	49.00 ± 8.80; 8/19; 24.00 ± 3.30^b;50.00 ± 9.60; 18/10; 25.00 ± 3.70^b	No	10/12	1; 2	5
ZALESKI 2014⁶²	1	44.10 ± 0.80; 203/216; 26.40 ± 0.20^a;44.60 ± 1.50; 104/113; 26.50 ± 0.45^a	No (n:400);Yes (n:19)	80/24	1; 2	5
ZOU 2018⁶³	1	59.30 ± 7.28; 45/30; 23.80 ± 3.15^b;61.21 ± 7.59; 37/38; 25.21 ± 4.72^b	Yes	20/48	1; 2	5
NORMOTENSIVE
RENKE 2010⁶⁴	2	34.20 ± 6.94; 7/7; ND	Yes	40/12	2	3
VRTOVEC 2005¹⁵	1	67.00 ± 13.00; 41/35; ND67.00 ± 13.00; 41/35, ND	Yes	10/12	1; 2	2
NORMOTENSIVE AND HYPERLIPIDAEMIC
HAMAAD 2005¹⁴	1	67.00 ± 10.00; 19/3; ND^b;66.00 ± 10.00; 7/2; ND^b	Yes	40/12	1; 2	3
HORWICH 2011⁵	1	47.00 ± 14.00; 5/9; 31.00 ± 7.00^a;49.00 ± 17.00; 10/2; 31.00 ± 6.00^a	Yes	3/12	1; 2	5
KADOGLOU1 2010⁶⁵	1	64.76 ± 7.31; 30/35; ND^b	Yes	10 or 20/48	1	3
KADOGLOU2 2010⁶⁵	1	63.24 ± 6.76; 30/36; ND^b	Yes	80/48	1	3
MELENOVSK 2003²⁷	2	47.00 ± 8.00; 29/0; 27.80 ± 2.00^b	No	10/10	1	3
TOKUHISA 2018⁶⁶	2	64.10 ± 11.60; 8/2; 23.00 ± 4.10^b	Yes	10/8	1	4
HYPERTENSIVE AND NORMOLIPIDAEMIC
MANISTY 2009⁶⁷	1	79.00; 127/15; 28.50 ± 4.00^b	Yes	10/72	2	3
MARTIN-VENTURA 2008⁶⁸	1	70.00 ± 7.00; 21/5; ND^a	No	20/4	1	3
HYPERTENSIVE AND HYPERLIPIDAEMIC
FASSET 2010⁶⁹	1	60.20 ± 15.10; 80/43; 28.50 ± 6.00^b;60.30 ± 15.20; 44/21; 28.60 ± 6.10^b	Yes	10/144	1; 2	5
FASSET 2010⁷⁰	1	63.55 ± 15.60; 16/16; 28.50 ± 5.55^b	Yes	10/90	1; 2	5
FOGARI 2004⁷¹	2	56.30 ± 5.10; 22/23; ND^b	Yes	20/12	1	3
KANAKI 2013⁷²	1	59.70 ± 8.80; 12/13; 29.40 ± 4.30^b;58.80 ± 10.80; 12/13; 29.60 ± 3.80^b	Yes	10/26	1; 2	3
KANAKI 2012⁷³	1	59.70 ± 8.90; 12/13; 29.40 ± 4.30^b;58.80 ± 10.80; 12/13; 29.60 ± 3.80^b	Yes	10/26	1; 2	3
KOH 2011¹¹	2	-	No	20/8	1	3
MAGEN 2004⁷⁴	1	54.10 ± 13.50; 8/7; 27.90 ± 1.80^b;51.40 ± 12.80; 7/9; 27.70 ± 2.10^b	Yes	20/8	1; 2	3
RAISON 2002⁷⁵	1	56.10 ± 9.50; 7/4; 29.30 ± 3.50^b	Yes	10/12	1	5
HYPERTENSIVE
FERRIER 2002⁷⁶	2	60.00 ± 14.00; 18/4: ND^b	No	80/12	2	5
GOMES 2010¹⁶	2	54.00 ± 16.00; 9/4; 26.70 ± 1.00^b	Yes	20/3	2	5

Article¹

RCT² 1. Parallel 2. Cross-over

Age³; n (men/women)⁴; BMI⁵ (atorvastatin and placeboor total population)

Use of antihypertensive

Dose/weeks⁶

Group 1. Basal 2. Placebo

Jadad Scale

NORMOTENSIVE AND NORMOLIPIDAEMIC

BLESKE 2006⁵⁵

56.00 ± 11.00; 9/6; 29.39 ± 4.53^b

Yes

80/12

1; 2

JOYEUX-FAURE 2014⁵⁶

51.00 ± 12.00; 21/4; 28.58 ± 5.12^b;56.00 ± 9.00; 18/8; 28.70 ± 3.94^b

40/12

1; 2

MUKHERJEE 2008⁵⁷

47.92 ± 11.42; 40/31; 22.46 ± 3.76^b

10/24

ORR 2009⁵⁸

53.00 ± 2.00; 6/10; 31.90 ± 0.90^a;55.00 ± 3.00; 5/5; 31.10 ± 0.90^a

80/12

1; 2

PAULSEN 2008³⁵

33.66 ± 13.56; 13/7; 25.50 ± 3.19^b

80/4

PAULSEN 2010³⁶

51.00 ± 5.56; 15/6; 28.66 ± 4.77^b

80/2 days

RAJA-KHAN 2011⁵⁹

38.80 ± 4.30; 0/20; 40.10 ± 11.80^b;29.40 ± 5.80; 0/11; 36.00 ± 10.40^b

40/6

1; 2

RIAHI 2006⁶⁰

64.30 ± 8.90; 71/18; 28.40 ± 4.40^b

Yes

80/6

SZRAMKA 2007²¹

63.40 ± 7.17; 8/2; 29.39 ± 4.53^b

80/4

TERAMOTO 2014⁶¹

49.00 ± 8.80; 8/19; 24.00 ± 3.30^b;50.00 ± 9.60; 18/10; 25.00 ± 3.70^b

10/12

1; 2

ZALESKI 2014⁶²

44.10 ± 0.80; 203/216; 26.40 ± 0.20^a;44.60 ± 1.50; 104/113; 26.50 ± 0.45^a

No (n:400);Yes (n:19)

80/24

1; 2

ZOU 2018⁶³

59.30 ± 7.28; 45/30; 23.80 ± 3.15^b;61.21 ± 7.59; 37/38; 25.21 ± 4.72^b

Yes

20/48

1; 2

NORMOTENSIVE

RENKE 2010⁶⁴

34.20 ± 6.94; 7/7; ND

Yes

40/12

VRTOVEC 2005¹⁵

67.00 ± 13.00; 41/35; ND67.00 ± 13.00; 41/35, ND

Yes

10/12

1; 2

NORMOTENSIVE AND HYPERLIPIDAEMIC

HAMAAD 2005¹⁴

67.00 ± 10.00; 19/3; ND^b;66.00 ± 10.00; 7/2; ND^b

Yes

40/12

1; 2

HORWICH 2011⁵

47.00 ± 14.00; 5/9; 31.00 ± 7.00^a;49.00 ± 17.00; 10/2; 31.00 ± 6.00^a

Yes

3/12

1; 2

KADOGLOU1 2010⁶⁵

64.76 ± 7.31; 30/35; ND^b

Yes

10 or 20/48

KADOGLOU2 2010⁶⁵

63.24 ± 6.76; 30/36; ND^b

Yes

80/48

MELENOVSK 2003²⁷

47.00 ± 8.00; 29/0; 27.80 ± 2.00^b

10/10

TOKUHISA 2018⁶⁶

64.10 ± 11.60; 8/2; 23.00 ± 4.10^b

Yes

10/8

HYPERTENSIVE AND NORMOLIPIDAEMIC

MANISTY 2009⁶⁷

79.00; 127/15; 28.50 ± 4.00^b

Yes

10/72

MARTIN-VENTURA 2008⁶⁸

70.00 ± 7.00; 21/5; ND^a

20/4

HYPERTENSIVE AND HYPERLIPIDAEMIC

FASSET 2010⁶⁹

60.20 ± 15.10; 80/43; 28.50 ± 6.00^b;60.30 ± 15.20; 44/21; 28.60 ± 6.10^b

Yes

10/144

1; 2

FASSET 2010⁷⁰

63.55 ± 15.60; 16/16; 28.50 ± 5.55^b

Yes

10/90

1; 2

FOGARI 2004⁷¹

56.30 ± 5.10; 22/23; ND^b

Yes

20/12

KANAKI 2013⁷²

59.70 ± 8.80; 12/13; 29.40 ± 4.30^b;58.80 ± 10.80; 12/13; 29.60 ± 3.80^b

Yes

10/26

1; 2

KANAKI 2012⁷³

59.70 ± 8.90; 12/13; 29.40 ± 4.30^b;58.80 ± 10.80; 12/13; 29.60 ± 3.80^b

Yes

10/26

1; 2

KOH 2011¹¹

20/8

MAGEN 2004⁷⁴

54.10 ± 13.50; 8/7; 27.90 ± 1.80^b;51.40 ± 12.80; 7/9; 27.70 ± 2.10^b

Yes

20/8

1; 2

RAISON 2002⁷⁵

56.10 ± 9.50; 7/4; 29.30 ± 3.50^b

Yes

10/12

HYPERTENSIVE

FERRIER 2002⁷⁶

60.00 ± 14.00; 18/4: ND^b

80/12

GOMES 2010¹⁶

54.00 ± 16.00; 9/4; 26.70 ± 1.00^b

Yes

20/3

Table 1

Open in new tab

Summary of studies included in the meta-analysis of blood pressure, heart rate, HRV, and baroreflex in randomized clinical trials. Included studies were stratified according to population characteristics.

Article¹	RCT² 1. Parallel 2. Cross-over	Age³; n (men/women)⁴; BMI⁵ (atorvastatin and placeboor total population)	Use of antihypertensive	Dose/weeks⁶	Group 1. Basal 2. Placebo	Jadad Scale
NORMOTENSIVE AND NORMOLIPIDAEMIC
BLESKE 2006⁵⁵	2	56.00 ± 11.00; 9/6; 29.39 ± 4.53^b	Yes	80/12	1; 2	5
JOYEUX-FAURE 2014⁵⁶	1	51.00 ± 12.00; 21/4; 28.58 ± 5.12^b;56.00 ± 9.00; 18/8; 28.70 ± 3.94^b	No	40/12	1; 2	5
MUKHERJEE 2008⁵⁷	1	47.92 ± 11.42; 40/31; 22.46 ± 3.76^b	No	10/24	2	3
ORR 2009⁵⁸	1	53.00 ± 2.00; 6/10; 31.90 ± 0.90^a;55.00 ± 3.00; 5/5; 31.10 ± 0.90^a	No	80/12	1; 2	3
PAULSEN 2008³⁵	2	33.66 ± 13.56; 13/7; 25.50 ± 3.19^b	No	80/4	2	4
PAULSEN 2010³⁶	2	51.00 ± 5.56; 15/6; 28.66 ± 4.77^b	No	80/2 days	2	4
RAJA-KHAN 2011⁵⁹	1	38.80 ± 4.30; 0/20; 40.10 ± 11.80^b;29.40 ± 5.80; 0/11; 36.00 ± 10.40^b	No	40/6	1; 2	3
RIAHI 2006⁶⁰	2	64.30 ± 8.90; 71/18; 28.40 ± 4.40^b	Yes	80/6	2	5
SZRAMKA 2007²¹	2	63.40 ± 7.17; 8/2; 29.39 ± 4.53^b	No	80/4	2	5
TERAMOTO 2014⁶¹	1	49.00 ± 8.80; 8/19; 24.00 ± 3.30^b;50.00 ± 9.60; 18/10; 25.00 ± 3.70^b	No	10/12	1; 2	5
ZALESKI 2014⁶²	1	44.10 ± 0.80; 203/216; 26.40 ± 0.20^a;44.60 ± 1.50; 104/113; 26.50 ± 0.45^a	No (n:400);Yes (n:19)	80/24	1; 2	5
ZOU 2018⁶³	1	59.30 ± 7.28; 45/30; 23.80 ± 3.15^b;61.21 ± 7.59; 37/38; 25.21 ± 4.72^b	Yes	20/48	1; 2	5
NORMOTENSIVE
RENKE 2010⁶⁴	2	34.20 ± 6.94; 7/7; ND	Yes	40/12	2	3
VRTOVEC 2005¹⁵	1	67.00 ± 13.00; 41/35; ND67.00 ± 13.00; 41/35, ND	Yes	10/12	1; 2	2
NORMOTENSIVE AND HYPERLIPIDAEMIC
HAMAAD 2005¹⁴	1	67.00 ± 10.00; 19/3; ND^b;66.00 ± 10.00; 7/2; ND^b	Yes	40/12	1; 2	3
HORWICH 2011⁵	1	47.00 ± 14.00; 5/9; 31.00 ± 7.00^a;49.00 ± 17.00; 10/2; 31.00 ± 6.00^a	Yes	3/12	1; 2	5
KADOGLOU1 2010⁶⁵	1	64.76 ± 7.31; 30/35; ND^b	Yes	10 or 20/48	1	3
KADOGLOU2 2010⁶⁵	1	63.24 ± 6.76; 30/36; ND^b	Yes	80/48	1	3
MELENOVSK 2003²⁷	2	47.00 ± 8.00; 29/0; 27.80 ± 2.00^b	No	10/10	1	3
TOKUHISA 2018⁶⁶	2	64.10 ± 11.60; 8/2; 23.00 ± 4.10^b	Yes	10/8	1	4
HYPERTENSIVE AND NORMOLIPIDAEMIC
MANISTY 2009⁶⁷	1	79.00; 127/15; 28.50 ± 4.00^b	Yes	10/72	2	3
MARTIN-VENTURA 2008⁶⁸	1	70.00 ± 7.00; 21/5; ND^a	No	20/4	1	3
HYPERTENSIVE AND HYPERLIPIDAEMIC
FASSET 2010⁶⁹	1	60.20 ± 15.10; 80/43; 28.50 ± 6.00^b;60.30 ± 15.20; 44/21; 28.60 ± 6.10^b	Yes	10/144	1; 2	5
FASSET 2010⁷⁰	1	63.55 ± 15.60; 16/16; 28.50 ± 5.55^b	Yes	10/90	1; 2	5
FOGARI 2004⁷¹	2	56.30 ± 5.10; 22/23; ND^b	Yes	20/12	1	3
KANAKI 2013⁷²	1	59.70 ± 8.80; 12/13; 29.40 ± 4.30^b;58.80 ± 10.80; 12/13; 29.60 ± 3.80^b	Yes	10/26	1; 2	3
KANAKI 2012⁷³	1	59.70 ± 8.90; 12/13; 29.40 ± 4.30^b;58.80 ± 10.80; 12/13; 29.60 ± 3.80^b	Yes	10/26	1; 2	3
KOH 2011¹¹	2	-	No	20/8	1	3
MAGEN 2004⁷⁴	1	54.10 ± 13.50; 8/7; 27.90 ± 1.80^b;51.40 ± 12.80; 7/9; 27.70 ± 2.10^b	Yes	20/8	1; 2	3
RAISON 2002⁷⁵	1	56.10 ± 9.50; 7/4; 29.30 ± 3.50^b	Yes	10/12	1	5
HYPERTENSIVE
FERRIER 2002⁷⁶	2	60.00 ± 14.00; 18/4: ND^b	No	80/12	2	5
GOMES 2010¹⁶	2	54.00 ± 16.00; 9/4; 26.70 ± 1.00^b	Yes	20/3	2	5

Article¹	RCT² 1. Parallel 2. Cross-over	Age³; n (men/women)⁴; BMI⁵ (atorvastatin and placeboor total population)	Use of antihypertensive	Dose/weeks⁶	Group 1. Basal 2. Placebo	Jadad Scale
NORMOTENSIVE AND NORMOLIPIDAEMIC
BLESKE 2006⁵⁵	2	56.00 ± 11.00; 9/6; 29.39 ± 4.53^b	Yes	80/12	1; 2	5
JOYEUX-FAURE 2014⁵⁶	1	51.00 ± 12.00; 21/4; 28.58 ± 5.12^b;56.00 ± 9.00; 18/8; 28.70 ± 3.94^b	No	40/12	1; 2	5
MUKHERJEE 2008⁵⁷	1	47.92 ± 11.42; 40/31; 22.46 ± 3.76^b	No	10/24	2	3
ORR 2009⁵⁸	1	53.00 ± 2.00; 6/10; 31.90 ± 0.90^a;55.00 ± 3.00; 5/5; 31.10 ± 0.90^a	No	80/12	1; 2	3
PAULSEN 2008³⁵	2	33.66 ± 13.56; 13/7; 25.50 ± 3.19^b	No	80/4	2	4
PAULSEN 2010³⁶	2	51.00 ± 5.56; 15/6; 28.66 ± 4.77^b	No	80/2 days	2	4
RAJA-KHAN 2011⁵⁹	1	38.80 ± 4.30; 0/20; 40.10 ± 11.80^b;29.40 ± 5.80; 0/11; 36.00 ± 10.40^b	No	40/6	1; 2	3
RIAHI 2006⁶⁰	2	64.30 ± 8.90; 71/18; 28.40 ± 4.40^b	Yes	80/6	2	5
SZRAMKA 2007²¹	2	63.40 ± 7.17; 8/2; 29.39 ± 4.53^b	No	80/4	2	5
TERAMOTO 2014⁶¹	1	49.00 ± 8.80; 8/19; 24.00 ± 3.30^b;50.00 ± 9.60; 18/10; 25.00 ± 3.70^b	No	10/12	1; 2	5
ZALESKI 2014⁶²	1	44.10 ± 0.80; 203/216; 26.40 ± 0.20^a;44.60 ± 1.50; 104/113; 26.50 ± 0.45^a	No (n:400);Yes (n:19)	80/24	1; 2	5
ZOU 2018⁶³	1	59.30 ± 7.28; 45/30; 23.80 ± 3.15^b;61.21 ± 7.59; 37/38; 25.21 ± 4.72^b	Yes	20/48	1; 2	5
NORMOTENSIVE
RENKE 2010⁶⁴	2	34.20 ± 6.94; 7/7; ND	Yes	40/12	2	3
VRTOVEC 2005¹⁵	1	67.00 ± 13.00; 41/35; ND67.00 ± 13.00; 41/35, ND	Yes	10/12	1; 2	2
NORMOTENSIVE AND HYPERLIPIDAEMIC
HAMAAD 2005¹⁴	1	67.00 ± 10.00; 19/3; ND^b;66.00 ± 10.00; 7/2; ND^b	Yes	40/12	1; 2	3
HORWICH 2011⁵	1	47.00 ± 14.00; 5/9; 31.00 ± 7.00^a;49.00 ± 17.00; 10/2; 31.00 ± 6.00^a	Yes	3/12	1; 2	5
KADOGLOU1 2010⁶⁵	1	64.76 ± 7.31; 30/35; ND^b	Yes	10 or 20/48	1	3
KADOGLOU2 2010⁶⁵	1	63.24 ± 6.76; 30/36; ND^b	Yes	80/48	1	3
MELENOVSK 2003²⁷	2	47.00 ± 8.00; 29/0; 27.80 ± 2.00^b	No	10/10	1	3
TOKUHISA 2018⁶⁶	2	64.10 ± 11.60; 8/2; 23.00 ± 4.10^b	Yes	10/8	1	4
HYPERTENSIVE AND NORMOLIPIDAEMIC
MANISTY 2009⁶⁷	1	79.00; 127/15; 28.50 ± 4.00^b	Yes	10/72	2	3
MARTIN-VENTURA 2008⁶⁸	1	70.00 ± 7.00; 21/5; ND^a	No	20/4	1	3
HYPERTENSIVE AND HYPERLIPIDAEMIC
FASSET 2010⁶⁹	1	60.20 ± 15.10; 80/43; 28.50 ± 6.00^b;60.30 ± 15.20; 44/21; 28.60 ± 6.10^b	Yes	10/144	1; 2	5
FASSET 2010⁷⁰	1	63.55 ± 15.60; 16/16; 28.50 ± 5.55^b	Yes	10/90	1; 2	5
FOGARI 2004⁷¹	2	56.30 ± 5.10; 22/23; ND^b	Yes	20/12	1	3
KANAKI 2013⁷²	1	59.70 ± 8.80; 12/13; 29.40 ± 4.30^b;58.80 ± 10.80; 12/13; 29.60 ± 3.80^b	Yes	10/26	1; 2	3
KANAKI 2012⁷³	1	59.70 ± 8.90; 12/13; 29.40 ± 4.30^b;58.80 ± 10.80; 12/13; 29.60 ± 3.80^b	Yes	10/26	1; 2	3
KOH 2011¹¹	2	-	No	20/8	1	3
MAGEN 2004⁷⁴	1	54.10 ± 13.50; 8/7; 27.90 ± 1.80^b;51.40 ± 12.80; 7/9; 27.70 ± 2.10^b	Yes	20/8	1; 2	3
RAISON 2002⁷⁵	1	56.10 ± 9.50; 7/4; 29.30 ± 3.50^b	Yes	10/12	1	5
HYPERTENSIVE
FERRIER 2002⁷⁶	2	60.00 ± 14.00; 18/4: ND^b	No	80/12	2	5
GOMES 2010¹⁶	2	54.00 ± 16.00; 9/4; 26.70 ± 1.00^b	Yes	20/3	2	5

Author, year of publication (reference); ²RCT: Randomized Clinical Trials; ³Age (year, mean ± standard error or deviation); ⁴n (men/women); ⁵ BMI: Body Mass Index (kg/m², mean ± standard error or deviation); ⁶mg.day⁻¹/weeks. HRV: heart rate variability; ND: not determined. ^ameans studies that used standard error; ^bmeans studies that used standard deviation.

This Feature Is Available To Subscribers Only